Esophagus Cancer Clinical Trial
Official title:
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial
This study aims to assess the efficacy of durvalumab in combination with radiochemotherapy (FOLFOX and IMRT) and then as maintenance therapy for treating patients with localised unresectable oesophageal cancer. This is a randomized, French national, multicentre, comparative phase II trial
ARION study will randomize 120 patients, in 12 centers in France, according to a ratio 1:1 in the following arm of treatment: - Standard and experimental arm: Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of: - 50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET) - 45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node FOLFOX 4 simplified protocol, 1 infusion every 2 weeks (q2w) during 3 months starting with radiotherapy (+/- 1 day): - IV oxaliplatin 85 mg/m² in 2 h on day 1 (D1) - IV Leucovorin 200 mg/m² in 2 h on D1, followed by - IV 5-FU 400 mg/m² in 10 minutes on D1 followed by - IV continuous infusion 5-FU 2400 mg/m² in 46 h - Experimental arm: Concomitant administration of durvalumab: Every 4 weeks during concurrent FOLFOX (dose: 1500 mg) and after FOLFOX completion (total of 12 months of treatment). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
| Completed |
NCT00201747 -
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05023928 -
Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer
|
Phase 1 | |
| Recruiting |
NCT03941626 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Recruiting |
NCT02988921 -
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy
|
N/A | |
| Terminated |
NCT02797405 -
Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay
|
N/A | |
| Completed |
NCT02979691 -
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03347630 -
Pre-operative MRI of Esophagus Cancer
|
N/A | |
| Completed |
NCT00193141 -
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT05626309 -
Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer
|
N/A | |
| Completed |
NCT05615129 -
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
|
||
| Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
| Terminated |
NCT03108885 -
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
|
||
| Recruiting |
NCT04046575 -
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
|
Phase 1 | |
| Recruiting |
NCT06126406 -
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT03467529 -
Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study
|
||
| Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 |